Julia A Chapman MD
Gynecologic Oncology, Urogynecology & Pelvic Reconstructive Surgery
Associate Professor, Obstetrics and Gynecology, University Kansas School of Medicine
Join to View Full Profile
10600 Quivira RdSte 130Overland Park, KS 66215
Phone+1 913-541-5550
Fax+1 913-541-5528
Dr. Chapman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (Irvine)Residency, Obstetrics and Gynecology, 1991 - 1994- University of California (Irvine)Fellowship, Urogynecology and Reconstructive Pelvic Surgery (Obgyn), 1994
Union Memorial HospitalFellowship, Gynecologic Oncology, 1990- University of California (Irvine)Residency, Obstetrics and Gynecology, 1985 - 1989
University of California, Irvine, School of MedicineClass of 1985
Certifications & Licensure
MI State Medical License 2024 - 2027
NM State Medical License 2024 - 2027
CA State Medical License 1987 - 2026
MO State Medical License 1994 - 2026
MT State Medical License 2024 - 2026
IN State Medical License 2024 - 2025
KS State Medical License 1994 - 2025
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
- Join now to see all
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers Start of enrollment: 2008 Jul 01
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
- Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Start of enrollment: 2010 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 32 citationsCediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.Jung-Min Lee, Richard G Moore, Sharad Ghamande, Min S Park, John P Diaz
Clinical Cancer Research. 2022-10-03 - 9 citationsDisparities in ovarian cancer survival at the only NCI-designated cancer center in Kansas.Shariska Petersen, Parmida Shahiri, Andrea Jewell, Lori Spoozak, Julia Chapman
American Journal of Surgery. 2021-04-01 - 46 citationsMicroRNA-205 promotes cell invasion by repressing TCF21 in human ovarian cancerJun Wei, Lahong Zhang, Jennifer Li, Shuguang Zhu, Minghui Tai
Journal of Ovarian Research. 2017-05-05
Press Mentions
Benefits of High-Dose Vitamin C for Ovarian Cancer PatientsFebruary 6th, 2014
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
